TRIPEPI, GIOVANNI LUIGI
 Distribuzione geografica
Continente #
EU - Europa 30
Totale 30
Nazione #
IT - Italia 30
Totale 30
Città #
Rome 22
Gioiosa Ionica 8
Totale 30
Nome #
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia, file 2dbc7cb5-e93e-4c87-ac6d-d70193703aae 4
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials, file 5e146688-8155-4947-b4c6-a2cc0f6836c3 4
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients, file 730e8026-212b-4a79-b648-e4d094ddcbcb 4
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials, file 83e09d9e-4612-4446-88a1-01a710493976 4
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol, file f5a03718-9a3d-420f-bd65-2034a9adc049 4
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma, file 81c052a3-3263-4024-bd4f-df3edaa1e73a 2
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials, file 85b4b71b-b9a2-4815-a6d4-f3b29133abc6 2
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study, file abfaf3c2-c279-4cf4-84f0-01ebd97acdbd 2
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases, file b1811dac-0762-4cdd-93d2-5a90732f7562 2
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia, file e806c803-be51-401a-9258-acba8414b73b 2
Totale 30
Categoria #
all - tutte 30
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202430 0 0 0 0 0 22 8 0 0 0 0 0
Totale 30